4-Antibody AG Meets Next Milestone in Boehringer Ingelheim Collaboration
4-Antibody AG announced the successful completion of a second milestone in its ongoing collaboration with Boehringer Ingelheim. This second milestone triggered an undisclosed fee payment.
4-Antibody’s R&D collaboration with Boehringer Ingelheim commenced in early 2010 and is a long-term collaboration to discover and develop fully human therapeutic antibodies for a number of targets in various disease indications. The collaboration centres on 4-Antibody’s proprietary high throughput in vitro Retrocyte Display® technology for rapid antibody discovery and development of fully human antibodies against novel targets nominated by Boehringer Ingelheim.
Robert Burns, 4-Antibody’s CEO, said: “Not only do you want your collaborations to serve an important role in validating your technology, but you also want your partners to be sufficiently happy that they continue to pay milestone payments as successful programme targets are achieved. We set out with our high throughput in vitro Retrocyte Display® technology to show we can take all the advantages of in vivo as well as in vitro platforms and combine them both without the limitations of these existing approaches. We see our continued partnering success as confirmation of that strategy.”
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous